News|Videos|October 30, 2023
CMS Reimbursement Shift in Prostate Cancer: Streamlining Radiotracer Payments
Author(s)David Albala, MD
David Albala, MD, discusses how starting October 1st, CMS will reimburse imaging centers directly, simplifying the process and removing reimbursement concerns for physicians ordering radiotracer tests.
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Advertisement
Advertisement
Trending on Urology Times
1
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
2
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
3
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
4
PSMA PET Radiotracers and Access Barriers in Prostate Cancer
5